Who We Are
We are a pre-commercial biopharmaceutical company dedicated to bringing a novel treatment to people living with migraine. We currently have one FDA approved treatment indicated for the acute treatment of migraine. Our treatments incorporate our advanced SMART platform to overcome the limitations of other delivery technologies and available options.
Since our inception in 2016, we have focused on combining great science, cutting-edge technology and proven drug therapies to create improved therapeutic products that address the significant unmet needs of patients.
Our team has extensive experience successfully developing, manufacturing and commercializing pharmaceutical products within both large and small companies, and we have particular expertise in the area of drug-device combination products delivered via inhalation.
Our Values
Our actions are driven by our values:
We are Patient-focused. We are Collaborative. We are Innovative. We are Science-driven. We act with Integrity.
Our Mission
At Satsuma Pharmaceuticals, our mission is to commercialize innovative therapeutic products that meaningfully improve the lives of people living with migraine.
Our Name
Our name, “Satsuma Pharmaceuticals” alludes to the origin of the novel dry-powder drug delivery technologies we use. These technologies were initially invented and developed by a team working at Satsuma co-founder Shin Nippon Biomedical Laboratories, Ltd. in Kagoshima, Japan. Historically, during the pre-modern Tokugawa period in Japan, Kagoshima was known as the Satsuma Domain and considered one of the most powerful and prominent of Japan’s feudal domains. Like our cultural values, the leadership of the Satsuma Domain maintained a keen interest in technology, innovation and external ideas and thinking. Originally exported from the Satsuma/Kagoshima area to the U.S. and today known as one of the sweetest of all citrus fruits, the satsuma orange embodied in our logo values our company’s Japanese roots.